PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.

Sean P MartinValerie FakoHien DangDana A DominguezSubreen KhatibLichun MaHaiyang WangWei ZhengXin Wei Wang

Published in: Journal of experimental & clinical cancer research : CR (2020)

Elevated PKM2 is associated with treatment resistance and abbreviated survival in patients receiving TACE. Elevated PKM2 in vitro is associated with increased utilization of the glycolysis pathway, resulting in oxygen independent cell metabolism. Through PKM2 knockdown as well as with pharmacologic inhibition with shikonin, non-responder cells can be reprogrammed to act as responders and could improve TACE efficacy in patients.

Keyphrases

end stage renal disease
induced apoptosis
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
single cell
cell cycle arrest
stem cells
oxidative stress
cell therapy
cell proliferation
endoplasmic reticulum stress
combination therapy
liver metastases